More than 12,000 jobs are being axed by two of Britain’s leading energy companies on the back of lower oil prices and major internal restructuring.
Uber, the taxi-app firm, is facing legal action over whether it affords its drivers basic rights and treats them as employees rather than “partners” or “contractors”.
Quintain Estates and Development, the developer behind Wembley Arena, has been bought by US private equity group Lone Star for £700m.
Nearly two-thirds of companies face "significant" cyberattacks on a daily or weekly basis, according to an Accenture survey of senior executives across the globe.
The GlaxoSmithKline CEO, Sir Andrew Witty, said the Chinese drug market has slowed down dramatically over the past year but insisted that the drugmaker’s own business is stabilising, as it unveiled second-quarter results that beat City expectations.
Amazon is proposing that a pristine slice of airspace above the world’s cities and suburbs should be set aside for the deployment of high-speed aerial drones capable of flying robotically with virtually no human interference.
Ford Motor delivered quarterly earnings that topped analysts' expectations on Tuesday, based on the continued strength of North American sales, led by its popular F-150 pickup truck.
Energy giant Chevron will eliminate about 1,500 job positions in an effort to cut costs, the company reported Tuesday.
BP, the oil giant, announced a second-quarter replacement cost loss of $6.3 billion, and warned low oil prices are here to stay.
A shortage of bricklayers, carpenters and site managers threatens to derail the construction sector’s recovery, an industry group has warned after fresh evidence of recruitment struggles at building companies.
BP is facing a row over boardroom pay at its annual meeting after a leading City investor warned it intended to vote against a $20m (£14m) package for chief executive Bob Dudley.
Barack Obama’s derailment of Pfizer’s $160bn (£114bn) merger with Allergan sparked immediate speculation on Wednesday that the US drugs company would turn its attention to another big pharmaceutical takeover.